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pWe are delighted to provide readers of the Journal with this
review of major scientific work published in the field of
interventional cardiology in 2010. In addition, we have
included late-breaking trials presented at the American
College of Cardiology, Transcatheter Cardiovascular Ther-
apeutics, European Society of Cardiology, and American
Heart Association conferences. We hope that the paper will
provide a broad overview of the field for general cardiolo-
gists, as well as a framework for more detailed study for
those with a specific interest in interventional cardiology.
Structural Heart Disease
Aortic valve replacement. Perhaps the most important
and exciting report from 2010 was publication of the first
randomized trial of transcatheter aortic valve implantation
(TAVI) for aortic stenosis (AS). The PARTNER (Place-
ment of Aortic Transcatheter Valves) trial randomly as-
signed 358 high-risk patients with severe AS who were not
suitable candidates for surgery to standard therapy (includ-
ing balloon aortic valvuloplasty) or TAVI with the Edwards
SAPIEN balloon-expandable bovine pericardial valve (Ed-
wards Lifesciences, Irvine, California) (1). The mean STS
(Society of Thoracic Surgeons) score was 11.6  6.0%. The
TAVI arm had a dramatically lower rate of death at 1 year
compared with the standard therapy arm (30.7% vs. 50.7%,
p  0.001) (Fig. 1). The TAVI patients were less likely to
have class III or IV heart failure (25.2% vs. 58%, p 0.001).
higher incidence of stroke and major vascular complica-
ions was observed in the TAVI arm. There was no
chocardiographic evidence of valve dysfunction at 1 year.
esults of this landmark trial will revolutionize the care of
noperable AS patients.
The year also saw many other scientific reports regarding
AVI. Gurvitch et al. (2) reported durability of the Ed-
ards valve in patients beyond 3 years in a large patient
ohort. Several institutional registries reported excellent
linical outcomes in high-risk patients (3–5). In a large
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both transfemoral and transapical) procedural success was
bserved in 93.8% (6). Stroke occurred in 2.5%. Thirty-day
ortality was 6.3% in transfemoral patients and 10.3% in
ransapical patients. Clavel et al. (7) compared the effects of
AVI and surgical aortic valve implantation on left ventric-
lar (LV) function in patients with reduced baseline ejection
raction. At 1 year, TAVI was associated with significantly
reater recovery of LV function compared with surgery
change in LV ejection fraction 14  15% vs. 7  11%,
 0.005). In another report, Messika-Zeitoun et al. (8)
demonstrated significant differences in measurement of the
aortic annulus diameter using echocardiography and mul-
tislice computed tomography, which has important poten-
tial implications for valve sizing.
Sherif et al. (9) evaluated anatomic and procedural
predictors of paravalvular aortic regurgitation after implan-
tation of the CoreValve device (Medtronic, Minneapolis,
Minnesota). Key predictors of aortic regurgitation were:
1) the angle between the LV outflow tract and ascending
aorta; and 2) the depth of the CoreValve in the LV outflow
tract in relation to the annular plane (optimal distance 9.5
mm from noncoronary cusp).
Finally, 2 studies addressed stroke after TAVI (10,11).
With diffusion-weighted magnetic resonance imaging, evi-
dence of cerebral embolization was observed in 72% to 84%
of patients, but in almost all cases, this was clinically silent.
The presence of new cerebral lesions did not appear to
impact neurocognitive function at 3-month follow-up.
Mitral valve repair. Another major development this year
was presentation of data from the first randomized trial of
percutaneous versus surgical mitral valve repair, EVEREST II
(Endovascular Edge-to-Edge Repair Study) (12). A total of
279 patients with significant (3 to 4) mitral regurgitation
was randomly allocated on a 2:1 basis to catheter-based
repair with the MitraClip (Evalve, Inc., Menlo Park,
California) versus surgery (repair or replacement). At 30
days, the primary safety endpoint, a composite of major
adverse events, was markedly lower in the MitraClip arm
(9.6% vs. 57%, p  0.0001). Clinical success at 12 months
(the primary effectiveness endpoint) defined as freedom
from death, mitral valve surgery, or mitral regurgitation
2, was 72.4% in the device arm and 87.8% in the
surgical arm (p  0.0012 for noninferiority). Improvements
in LV function, functional class, and quality of life were
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Year in Interventional Cardiology May 31, 2011:2207–20similar in both treatment arms. These exciting data suggest
that percutaneous mitral repair with the MitraClip is an
important therapeutic option for patients with significant
mitral regurgitation. Future studies will address the long-
term durability of the procedure and results in lower risk
patient groups.
Patent foramen ovale closure. Results of another very
important trial in the structural heart disease field were
presented this year (13). The CLOSURE-I study evaluated
the safety and efficacy of patent foramen ovale closure in
patients with stroke or transient ischemic attack due to
presumed paradoxical embolism. In all, 909 patients were
randomly assigned to closure with the STARflex device
(NMT Medical, Boston, Massachusetts) or best medical
therapy (aspirin or warfarin). At 2 years, the primary
endpoint of stroke or transient ischemic attack was not
significantly different (5.9% in the device arm, 7.7% with
medical therapy, p  NS). A higher incidence of atrial
fibrillation and major vascular complications was also ob-
served in the device group. Despite a number of potential
limitations with the trial design, these results will undoubt-
edly have a negative impact on the use of patent foramen
ovale closure for prevention of neurological events after
cryptogenic stroke.
In other reports, van den Branden et al. (14) presented
results of a study using a septal occluder with a totally
biodegradable matrix, and Zimmerman et al. (15) presented
results of a first-in-human study using a novel “in-tunnel”
patent foramen ovale occluder device.
Elective Percutaneous Coronary Intervention
Left main coronary artery disease. Several publications
Figure 1 Kaplan-Meier Event Curves for
Time to Death From Any Cause
Kaplan-Meier event curves for time to death from any cause in patients with
severe aortic stenosis randomly assigned to transcatheter aortic valve implan-
tation (TAVI) or to standard therapy (including balloon aortic valvuloplasty). The
TAVI significantly reduced the rates of death from any cause (1). CI  confi-
dence interval.verified the long-term safety and efficacy of unprotected left mmain coronary artery (LMCA) stenting compared with
coronary artery bypass graft surgery (CABG). Park et al.
(16) evaluated 2,204 LMCA disease patients who were
treated with either percutaneous coronary intervention
(PCI), bare-metal stent (BMS), or drug-eluting stent
(DES), or CABG in a nonrandomized fashion. At a median
of 5.2 years of follow-up, death, myocardial infarction (MI),
or stroke was similar, but target vessel revascularization
(TVR) was higher in the PCI group. In a smaller cohort
with 10-year follow-up, mortality, MI, and stroke rates
remained equivalent (17). Chieffo et al. (18) reported 5-year
outcomes in 249 unprotected LMCA disease patients
treated with either DES or CABG (nonrandomized), and
found a significant reduction in composite death, MI, or
stroke in the DES group, but a higher rate of TVR (18).
The SYNTAX (Synergy Between PCI With TAXUS
and Cardiac Surgery) Investigators published 1-year out-
comes in the 705 patients with unprotected LMCA disease
randomly assigned to TAXUS stenting versus CABG (19).
Major adverse cardiovascular events (MACE) were similar
between the 2 groups; however, stroke was significantly
higher in the CABG cohort (2.7% vs. 0.3%, p  0.004).
Revascularization was higher in the PCI arm (11.8% vs.
6.5%, p  0.02). Low or intermediate SYNTAX scores
33) predicted good outcomes with PCI for unprotected
MCA (Fig. 2). At the Transcatheter Cardiovascular Ther-
peutics meeting, Serruys (20) confirmed these results were
aintained at 3-year follow-up. Similarly, among 452
iabetic patients with LMCA or 3-vessel disease in the
YNTAX trial (21), TVR was higher after TAXUS com-
ared with CABG, but death, stroke, and MI rates were
quivalent.
ultivessel disease. The MASS-II (Medicine, Angio-
lasty or Surgery Study) reported 10-year outcomes among
11 randomized patients with stable angina and multivessel
isease (22). Medical therapy was an inferior strategy
ompared with CABG and PCI, respectively, with lower
urvival (69% vs. 74.9% and 75.1%, p  0.089) and higher
nfarction (20.7% vs. 10.3% and 13.3%, p  0.01). Both
edical therapy and PCI had higher rates of revasculariza-
ion than CABG. The CARDia (Coronary Artery Revas-
ularization in Diabetes) trial randomized 510 diabetic
atients with multivessel disease to PCI (BMS or sirolimus-
luting stent [SES]) or CABG (23). One-year mortality was
dentical (3.2% vs. 3.2%), and combined death, MI, and
troke were similar (10.5% vs. 13.0%, p  0.39) between
ABG and PCI arms. Similarly, the ARTS-II (Arterial
evascularization Therapies Study II) found similar free-
om from death, MI, or stroke in the patients with
ultivessel disease treated with SES compared with
ABG, but superior to the BMS cohort from ARTS-I
24). Interestingly, in this era of short (3-month) duration
ual antiplatelet therapy (DAPT), 32% of the MACE
vents were attributed to stent thrombosis. In the SYNTAX
ultivessel cohort, stent thrombosis occurred in 4.1% of
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May 31, 2011:2207–20 Year in Interventional CardiologyTAXUS-treated patients, and by 3 years, a significant
increase in MI (7.1% vs. 3.3%, p  0.005) and increased
mortality (9.5% vs. 5.7%, p  0.02) was observed compared
ith CABG (25). In our opinion, these findings speak for
onger duration DAPT or for avoiding devices such as
aclitaxel-eluting stents (PES) thought to have higher stent
hrombosis rates compared with other DES.
ractional flow reserve guidance. Fractional flow reserve
easurement is useful to reduce adverse events in multives-
el disease patients undergoing PCI. The FAME (FFR
ersus Angiography for Multivessel Evaluation) trial ran-
omized 1,005 patients with multivessel disease. Among
esions with 50% to 70% stenosis, 35% were functionally
ignificant; lesions with 71% to 90% stenosis, 80% were
unctionally significant; and lesions 90%, 96% were func-
ionally significant (26). The group randomly assigned to
Figure 2 Kaplan-Meier Estimates of 1-Year MACCE
by Baseline SYNTAX Score Tertile
Kaplan-Meier estimates of 1-year major adverse cardiovascular and cerebrovas-
cular events (MACCE [all-cause death, myocardial infarction, stroke, and repeat
revascularization]) by baseline SYNTAX score tertile: patients with (A) low base-
line SYNTAX score (0 to 22); (B) intermediate baseline SYNTAX score (23 to
32); and (C) high baseline SYNTAX score (33) (19). CABG  coronary
artery bypass graft surgery (black lines); PCI  percutaneous coronary
intervention (blue lines). Figure by Craig Skaggs.ractional flow reserve had lower utilization of stents (1.9 vs. w.7, p  0.001) and reduced death or MI at 2 years (8.4%
s. 12.9%, p  0.02) (27).
ifurcation. Although a single stent strategy for bifurca-
ion lesions appears to be preferred when using BMS,
imited data exist regarding DES. The British Bifurcation
roup randomly assigned 500 patients with bifurcation
esions to simple versus 2-stent technique using DES (28).
s expected, the 2-stent technique was longer in duration
nd required more radiation, and also increased the risk of
eriprocedural MI. A Korean registry found lower rates of
evascularization when bifurcation lesions were treated with
ES rather than PES (29).
oronary total occlusion. A meta-analysis of 14 publica-
ions comparing DES with BMS among 4,394 patients
ith coronary total occlusion found that DES significantly
educed restenosis and reocclusion, with similar rates of
eath or MI compared with BMS (30).
igh-risk PCI. The BCIS (Balloon Pump Assisted Cor-
nary Intervention Study) randomized 301 patients with
xtensive multivessel disease and ejection fraction 30% to
ntra-aortic balloon pump versus none before PCI (31).
lthough fewer procedural complications occurred in the
ntra-aortic balloon pump group (1.3% vs. 10.7%, p 
.001), access site complications were increased (3.3% vs.
%, p  0.06) and MACE rates were similar. The authors
oncluded that the results did not support routine intra-
ortic balloon pump for high-risk coronary intervention.
ascular access and closure. Methods to reduce vascular
ccess complications have included use of radial access,
maller sheaths, modifying antithrombotics, and vascular
losure devices. The American Heart Association released a
cientific statement on arteriotomy closure devices conclud-
ng that, although arteriotomy closure devices (ACDs)
mprove patient comfort and shorten the time to ambula-
ion, they have not been shown to reduce vascular compli-
ations (32). We believe that this may be due, in part, to
igher complication rates of some devices (VASOSeal,
LC Medical Systems Inc., Franklin, Massachusetts) and
ack of studies enrolling highest risk patients. Interestingly,
trial randomizing 1,004 patients undergoing femoral
ccess to ultrasound versus fluoroscopic guidance (33) found
hat ultrasound was faster, and reduced the number of
ttempts, risk of venipuncture, and vascular complications
1.4% vs. 3.4%, p  0.04).
ontrast nephropathy. Prevention of contrast-induced
ephropathy remains a problem. In a Korean study of 382
iabetic patients, the use of sodium bicarbonate (1 h before,
h after) was not superior to saline hydration for 24 h (34).
n this study, the amount of contrast used and lower ejection
raction were predictors of contrast-induced nephropathy.
artorelli (35) reported a trial utilizing saline hydration with
orced diuresis with nurse monitoring compared with the
enalGuard device (PLC Medical Systems Inc.), which
utomatically gives intravenous hydration based on urine
utput. In this study, after 30 min of hydration, furosemide
as given (0.5 mg/kg, and 20% of patients received addi-
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Year in Interventional Cardiology May 31, 2011:2207–20tional doses) resulting in urine output of 826  342 ml/h.
Accordingly, the RenalGuard device hydrated the patient at
a rate of 1 l/h and rates of contrast-induced nephropathy
and MACE were reduced. We do not know whether these
results were due to the adverse effects of furosemide in a
control group that was not adequately hydrated.
Unfortunately, 2010 was a bad year for N-acetylcysteine.
Two trials utilizing high doses (1,200 mg twice a day for
48 h) found no advantage over saline hydration alone in a
randomized trial of 250 STEMI patients (36) or in a
randomized trial of 2,308 high-risk patients (37). In sum-
mary, these data suggest that N-acetylcysteine is not bene-
ficial, and hydration with sodium bicarbonate is more
convenient but not superior to prolonged hydration with
normal saline.
Intravascular ultrasonography. One method to poten-
tially improve outcomes after DES is to perform intravas-
cular ultrasonography (IVUS) to optimize stent deploy-
ment. However, Colombo (38) reported a trial randomizing
284 patients with complex lesions to the IVUS versus
angiography-guided stent deployment. Although IVUS re-
sulted in larger lumen measurements, there was no differ-
ence in MACE, target lesion revascularization (TLR) (7.0%
vs. 5.0%), or stent thrombosis (0.7% vs. 0.0%) compared
with angiography-guided implantation.
Drug-Eluting Stents
DES versus BMS. It has been suggested that large vessels
treated with a DES may have higher adverse events com-
pared with BMS. Kaiser et al. (39) randomly assigned 2,314
patients with large coronaries (3.0 mm) to DES (SES or
everolimus-eluting stent [EES]) versus BMS. The DES
was superior at reducing TVR, while rates of death and MI
were similar. The benefit of DES in a saphenous vein graft
disease is also controversial. Latib et al. (40) performed a
retrospective review of 127 patients receiving DES in a
saphenous vein graft compared with 131 patients receiving
BMS. Although the DES group was far more complex,
clinical outcomes were similar, and a propensity analysis
suggested reduction in TVR (hazard ratio: 0.31, 95%
confidence interval: 0.14 to 0.66; p  0.002).
DES thrombosis. Stent thrombosis (ST) continues to be a
topic of interest, and was reviewed in a JACC White Paper
by Holmes et al. (41). The RESTART (Registry of Stent
Thrombosis for Review and Reevaluation) reported 611
patients with definite ST of a SES (322 early, 105 late, and
184 very late,1 year) (42). Mortality 1 year after ST varied
depending on the timing of ST: 22.4% for early, 23.5% for
late, and 10.5% for very late. Predictors of late and very late
ST included chronic kidney disease, prior PCI, PCI of total
occlusion, and age 65 years. When implanting multiple
DES within the same vessel, it may be better to avoid
overlap. In 1 study, overlapping DES was associated with
more late loss, TLR, death or MI compared with multiple
non overlapped DES or single DES (43). 0Second-generation DES. Second-generation DES
(zotarolimus-eluting stent [ZES] and EES) were developed
to reduce restenosis, but also be more deliverable and reduce
ST compared with first-generation DES. Several studies
were presented regarding ZES. Leon et al. (44,45) reported
a trial of 1,548 patients randomly allocated to a ZES or
PES. The PES was associated with higher rates of peripro-
cedural MI and very late stent thrombosis, but similar
definite/probable ST and TLR at 3-year follow-up (44,45).
Park et al. (46) randomly assigned 2,645 patients to ZES,
PES, or SES and found the SES superior to both ZES and
PES at reducing TVR and ST. Similarly, a European trial of
2,332 patients found the ZES inferior to SES with regard to
MACE (10% vs. 5%, p  0.0001) at 18 months (47).
Numerous trials evaluating EES were published or pre-
sented in 2010. Stone et al. (48) randomized 3,687 patients
to EES or PES and found EES resulted in a significantly
lower rate of target lesion failure at 1 year (4.2% vs. 6.8%,
p  0.001). Similarly, the COMPARE trial (n  1,800)
ound significant reductions in TVR, MI, and ST with
ience compared with the Taxus Liberté PES (49). The
enefit of EES was even greater at 2 years, with an absolute
ifference of 4.7% in the rate of the combined endpoint of
eath, nonfatal MI, and TVR (50). In another trial,
ibichini (51) found a significantly lower rate of late loss at
months with EES compared with PES (0.08 mm vs. 0.22
m, p  0.018).
The first randomized comparisons of EES and SES were
lso reported in 2010 (Table 1). Kim (52) found a lower
ncidence of angiographic late loss with EES. Two random-
zed trials demonstrated similar clinical outcomes with EES
53,54), while a propensity-matched study found a lower
ate of ST with EES (55).
Serruys et al. (56) compared 2,292 patients who were
andomly assigned to EES or ZES, and found target lesion
ailure at 1 year was similar between both second-generation
tents.
To summarize, these data suggest that PES is inferior in
any respects, and unlike early reports, the ZES does not
ppear to reduce the risk of ST compared with SES or EES.
linical and angiographic results seem to be best in SES- or
ES-treated groups.
ES restenosis. The optimal treatment strategy for treat-
ent of DES restenosis has not been well established. The
-Cypher registry reported 1,094 restenotic lesions after SES
hat were treated with additional SES (n  537) or
ercutaneous transluminal coronary angiography (n  557)
57). Recurrent TLR occurred less frequently in the repeat
ES group (23.8% vs. 37.7%, p  0.0001) at 2-year
ollow-up. Some have suggested that a different drug should
e utilized after restenosis of DES. Mehilli et al. (58)
andomly assigned 450 patients with SES restenosis to PCI
ith repeat SES or switching to PES. Either strategy was
ssociated with comparable safety and efficacy (binary reste-
osis at 6 to 8 months: SES 19.6% vs. PES 20.6%, p 
.69). The CRISTAL trial randomly allocated 281 patients
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May 31, 2011:2207–20 Year in Interventional Cardiologywith DES restenosis (SES or PES) to SES versus percuta-
neous transluminal coronary angiography (59). Angio-
graphic outcomes at 9 to 12 months favored SES implan-
tation compared with percutaneous transluminal coronary
angiography (minimal lumen diameter 2.14  0.62 vs.
1.71 0.55, p 0.0001), with a trend toward reduced TVR.
onpolymer DES. Because polymer residue has been
mplicated as a potential etiologic factor for late adverse
vents after DES implantation, several groups have inves-
igated polymer-free stent platforms. Byrne et al. (60) found
xcellent angiographic and clinical outcomes at 2 years with
polymer-free rapamycin and probucol-eluting stent com-
ared with either a ZES (Endeavor, Medtronic, Santa Rosa,
alifornia) or permanent-polymer SES. In a larger 3,002-
atient randomized trial, the polymer-free rapamycin and
robucol-eluting stent was noninferior to a ZES (Endeavor
esolute) with comparable angiographic and clinical end-
oints at 12 months (61). Grube (62) reported excellent
2-month angiographic outcomes with a novel polymer-free
iolimus A9-eluting stent (BioFreedom, Biosensors Inter-
ational, Morges, Switzerland) compared with a PES
TAXUS Liberté [late loss 0.17 mm vs. 0.35 mm],
 0.001 for noninferiority).
ew DES. Kereiakes et al. (63) reported a randomized
tudy comparing a novel thin-strut (81 m) platinum
hromium alloy PES (Taxus Element, Boston Scientific,
atick, Massachusetts) to the Taxus Express PES in 1,262
atients. Clinical and angiographic endpoints at 12 months
ere similar between the 2 groups. A small randomized trial
emonstrated improved angiographic and clinical outcomes
ith a combined paclitaxel-eluting balloon plus endothelial
Studies of Everolimus-Eluting Stents Published or Reported in 2010Table 1 Studies of Everolimus-Eluting Stents Published or Repo
First Author (Ref. #) Acronym n Stents
EES vs. PES
Stone et al. (48) SPIRIT IV 3,687 XIENCE vs. TAXUS Express
Kedhi et al. (49) COMPARE 1,800 XIENCE vs. TAXUS Liberté
Ribichini (51) EXECUTIVE 200 XIENCE vs. TAXUS Liberté
EES vs. SES
Byrne (53) ISAR-TEST 4 1,304 XIENCE vs. Cypher
Jensen (54) SORT OUT IV 2,774 XIENCE V vs. Cypher Select
Kim (52) EXCELLENT 1,372 XIENCE V vs. Cypher Select
Raber (55) LESSON-I 2,684 XIENCE V vs. Cypher
EES vs. SES
Serruys et al. (56) RESOLUTE All
Comers
2,292 Resolute ZES vs. XIENCE V
EES  everolimus-eluting stent(s); LL  late loss; MACE  major adverse cardiovascular events; M
revascularization; TVR  target vessel revascularization; ZES  zotarolimus-eluting stent(s).rogenitor cell-capturing stent compared with endothelial fiprogenitor cell-capturing stent alone (64). In another trial,
Beijk et al. (65) found a higher rate of 1-year target vessel
failure (TVF) with an EPC stent compared with a PES
(17.3% vs. 10.6%).
Serruys et al. (66) reported results with a second-
generation bioresorbable EES. At 6 months, there was only
a 2% decrease in scaffold area, with late loss 0.19  0.18
m, and 96.8% strut coverage by optical coherence tomog-
aphy. These findings represent an exciting step forward in
he bioresorbable vascular scaffold field.
cute MI
ime to treatment. Several studies investigated the impact
f time to reperfusion on clinical outcomes. Brodie et al.
67) evaluated the impact of door-to-balloon time on
ortality depending on clinical risk and time to presenta-
ion in 4,548 nonshock acute MI patients. Short door-to-
alloon times (90 min) had greatest impact in patients
resenting early (90 min), especially in high-risk patients
TIMI [Thrombolysis In Myocardial Infarction] risk score
2) (67). A short door-to-balloon time had less impact on
ortality in patients presenting after 90 min. Lambert et al.
68) studied outcomes in a large registry of ST-segment
levation myocardial infarction (STEMI) patients in Que-
ec (n  2,356) (68). Patients who received reperfusion
herapy outside of guideline recommended maximum delay
30 min for fibrinolysis; 90 min for PCI) had significantly
igher 30-day mortality (6.6% vs. 3.3%). In another analy-
is, Terkelsen et al. (69) focused on system delay (time from
in 2010
Primary Endpoint Main Findings
et lesion failure (death, MI,
schemia-driven TLR) at 1 yr
2Rate of target-lesion failure at 1 yr with EES
(4.2% vs. 6.8%, p  0.001)2ST with EES
(0.17% vs. 0.85%, p  0.004)
posite death, MI, TVR within
2 months
2Endpoint with EES (6% vs. 9%, p  0.02)
tent late loss at 9 months 2Late loss with EES (0.08 mm vs. 0.22 mm)
th, MI, TLR at 2 years No difference in clinical outcomes at 2 yrs
CE at 9 months (death, MI,
efinite ST, clinically driven TVR)
EES noninferior to SES2Rate ST with EES
egment late loss at 9 months Similar rate of LL (EES 0.10 mm vs.
SES 0.05 mm, p  0.023 for
noninferiority)
pensity-matched comparison
eath/MI/TVR at 3 yrs
2Rate of events at 3 yrs with EES (14.9% vs.
18.0%, p  0.056)2Rate of ST with EES
(0.5% vs. 1.6%, p 0.01)
et lesion failure (death, MI,
linically indicated TLR) within 1 yr
Similar rate of primary endpoint (ZES 8.2% vs.
EES 8.3%) and other outcomes; ST 2.3%
with ZES, 1.5% with EES
yocardial infarction; SES  sirolimus-eluting stent(s); ST  stent thrombosis; TLR  target lesionrted
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Year in Interventional Cardiology May 31, 2011:2207–20delay was associated with worse survival in patients treated
with PCI (69).
Drug-eluting stents. Although DES improve short-term
outcomes in STEMI patients, it has been unclear whether
these benefits are sustained at late follow-up. Stone (70)
presented 3-year results of the HORIZONS-AMI (Har-
monizing Outcomes With Revascularization and Stents in
AMI) trial (70). Implantation of the Taxus PES resulted in
a 40% reduction in ischemic TLR at 3 years, without any
increased risk of stent thrombosis, reinfarction, or all-cause
mortality. Two other trials reported similar findings at 3
years with a significant reduction in MACE, driven primar-
ily by the lower rate of TLR with DES (mostly in the first
year) (71,72). One study provided 5-year follow-up data
(73), and reported no difference in MACE but a small
increased risk of very late stent thrombosis with a PES. An
increased risk of stent thrombosis was also observed in
another trial (74) when routine filter-based distal protection
was used during primary PCI. One potential factor that
might lead to late ST is stent malapposition. Guo et al. (75)
performed a detailed IVUS analysis of 241 patients with
baseline and 13-month imaging in the HORIZONS-AMI
trial (75). Acute stent malapposition was common in both
BMS and DES lesions (35% to 40%), with similar rates of
resolution in each group at follow-up. Conversely, late
acquired malapposition was more common in PES-treated
lesions compared with BMS-treated lesions (30.8% vs.
8.1%, p 0.023), due to positive remodeling and resolution
f thrombus/plaque. However, the clinical impact of late
cquired malapposition remains uncertain at this time.
nother trial reported that patients treated with a PES
ad a significant reduction in late loss at 12 months
ompared with a BMS, but there was no difference in
inary restenosis (76).
Stone et al. (77) also provided a clinically useful analysis
rom the HORIZONS trial to assist with stent selection in
MI patients. Patients with 2 or 3 well-known risk factors
or restenosis (insulin-treated diabetes mellitus, reference
essel diameter 3 mm, and lesion length 30 mm) had
he greatest benefit with a DES compared with BMS
12-month TLR 19.8% vs. 8.1%, p  0.003). Patients with
risk factor had a modest benefit (7.3% vs. 4.3%, p 0.02),
hereas patients with no risk factors had similar outcomes
o those with BMS.
hrombectomy. Use of rheolytic thrombectomy before
irect stenting was studied in a 501-patient multicenter
andomized trial (78). In contrast to prior studies, all
atients had angiographic evidence of thrombus (thrombus
rades 3 to 5). Early ST-segment resolution was more
requent in the rheolytic thrombectomy arm; however there
as no difference in final infarct size at 1 month. Event-free
urvival was higher in the rheolytic thrombectomy arm. In
nother report, Mongeon et al. (79) performed a Bayesian
eta-analysis of 21 trials of adjunctive thrombectomy andound that thrombectomy improved early markers of reper- pusion, but had no impact on 30-day mortality or clinical
utcomes.
djunctive agents. Several studies in 2010 evaluated novel
pproaches to enhance myocardial salvage. Three trials
nvestigated use of erythropoietin in patients with STEMI
2 studies used single-dose erythropoietin after reperfusion
80,81); 1 study used 3 doses after PCI (82). Overall, these
tudies demonstrated no benefit of erythropoietin on infarct
ize, ejection fraction, or LV remodeling. In 2 studies, a
igher incidence of adverse effects was observed in patients
reated with erythropoietin (80,82). In another report,
ewton et al. (83) presented results of a cardiac MRI
ubstudy (n  28) of a trial using cyclosporine before
eperfusion. At 6 months, the cyclosporine group had a
ignificant reduction in infarct size and LV end-systolic
olume compared with the control group. Two studies
valuated the cardioprotective effects of ischemic condition-
ng (84,85). In 1 trial, remote ischemic conditioning was
erformed en route to hospital using 4 cycles of 5-min blood
ressure cuff inflation-deflation (84). A higher rate of
yocardial salvage was observed in the ischemic condition-
ng arm. In the other trial, ischemic post-conditioning
erformed immediately after reperfusion (using 4 balloon
cclusions, each lasting 30 s), resulted in a 19% relative
eduction in infarct size (85).
CI after thrombolysis. A Norwegian trial evaluated the
afety and efficacy of immediate angioplasty versus
schemia-guided therapy after thrombolysis in 266 AMI
atients presenting to remote non-PCI hospitals (86). The
roup randomly assigned to immediate transfer for PCI had
educed ischemia at 30 days and improved composite
ndpoint of death, reinfarction, or stroke at 12 months.
orgia et al. (87) performed a meta-analysis of 7 trials of
outine PCI versus standard care after fibrinolysis. The early
outine invasive strategy was associated with significant
eductions in reinfarction and recurrent ischemia compared
ith standard therapy, both at 30 days and at 6 to 12
onths of follow-up.
Nielsen et al. (88) reported late follow-up (median 7.8
ears) of the DANAMI-2 (Danish Acute Myocardial
nfarction-2) trial in which 1,572 STEMI patients were
andomly allocated to PCI or fibrinolysis. The short-term
enefit of PCI over fibrinolysis was maintained at long-term
ollow-up with a reduced the risk of reinfarction and (11.7%
s. 18.5%) and death/reinfarction (34.8% vs. 41.3%).
ardiogenic shock. The optimal timing for intra-aortic
alloon pump support in patients with cardiogenic shock is
nclear. Findings of a retrospective study suggest that
ntra-aortic balloon pump insertion before PCI is associated
ith better outcomes compared with intra-aortic balloon
ump placement after PCI (89).
cute Coronary Syndromes
n early invasive strategy is currently recommended in
atients with non–ST-segment elevation acute coronary
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May 31, 2011:2207–20 Year in Interventional Cardiologysyndrome (ACS) and high-risk features. In 2010, Fox et al.
(90) performed a meta-analysis of 3 randomized trials (n 
5,467) comparing a routine early invasive versus selective
invasive strategy. Over 5 years, a routine early invasive
strategy was associated with a significant reduction in death
or myocardial infarction (14.7% vs. 17.9%, p  0.002)
ompared with the selective approach (greatest benefit was
bserved in the highest-risk patients). In contrast, Damman
t al. (91) provided 5-year follow-up of the ICTUS (Inva-
ive Versus Conservative Treatment in Unstable coronary
yndromes) trial, which randomized 1,200 troponin posi-
ive ACS patients to an early (24 to 48 h) invasive or
elective invasive strategy and found no difference in the
ncidence of death or MI (91).
In contrast to STEMI, the impact of time-to-PCI has
ot been well studied in ACS. Sorajja et al. (92) studied
utcomes in 7,749 patients in the ACUITY (Acute Cath-
terization and Urgent Intervention Triage Strategy) trial
ccording to timing of PCI. Delay to PCI 24 h was an
ndependent predictor of 30-day and 1-year mortality,
specially in patients with high-risk features. These data
uggest that urgent angiography and triage to revasculariza-
ion is important in ACS patients.
harmacotherapy
lopidogrel. DUAL ANTIPLATELET THERAPY. The optimal
uration of DAPT after DES implantation has not been
stablished. Park et al. (93) randomly assigned 2,701 pa-
ients who received a DES to continue DAPT or aspirin
lone after 12 months. At median follow-up of 19.2
onths, there was no significant difference in event rates
ncluding death, MI, stroke, or ST. A series of larger DAPT
rials are ongoing and will provide the basis for clinical
ecommendations regarding duration of DAPT.
LOADING DOSE. Clopidogrel pre-treatment has been
shown to improve clinical outcomes after PCI; however,
these studies did not evaluate a high-dose in laboratory
strategy. Di Sciascio et al. (94) randomly allocated 409
patients to clopidogrel pre-treatment (600 mg 4 to 8 h
before PCI) or to a clopidogrel 600 mg loading dose given
in the catheterization laboratory after angiography. At 30
days, there was no difference in clinical events, thus suggesting
the in-lab strategy is a reasonable alternative when patients
cannot be pre-treated. In another study, the same investigators
demonstrated that there is no benefit from reloading patients
who are on chronic clopidogrel therapy (95).
MAINTENANCE DOSE. The CURRENT OASIS-7 (Clopi-
dogrel and Aspirin Optimal Dose Usage to Reduce Recur-
rent Events–Seventh Organization to Assess Strategies in
Ischemic Symptoms) trial randomly allocated 17,000 ACS
patients undergoing PCI to double-dose clopidogrel (600
mg load and 150 mg/day  7 days followed by 75 mg/day)
versus conventional dosing (96). The double-dose group
had significant reductions in death, MI, and stroke, and a p42% decrease in ST, leading to rapid adoption of this
approach in many centers. Whether a higher dosing strategy
is also beneficial in patients with suboptimal platelet inhi-
bition has been in question. Price et al. (97) randomly
assigned 2,214 patients with high residual platelet reactivity
(platelet reactivity units 230) to high-dose (150 mg daily)
versus standard-dose clopidogrel for 6 months. High-dose
clopidogrel caused a modest improvement in platelet inhi-
bition; however, there was no difference in clinical events. In
another study, Sibbing et al. (98) found no benefit of
tapering clopidogrel or evidence of a rebound phenomenon
after discontinuing therapy.
PLATELET FUNCTION TESTING. Breet et al. (99) evaluated
the value of on-treatment platelet reactivity to predict
clinical outcomes measured using several different platelet
function assays. Interestingly, only 3 of 6 assays studied
provided prognostic information, and the predictive accu-
racy of these 3 tests was quite modest (area under the curve
between 0.61 and 0.63). These data suggest that routine
platelet function testing is not helpful in elective PCI.
GENOTYPING. Several studies evaluated CYP2C19 poly-
morphisms and the antiplatelet effect of clopidogrel. In a
meta-analysis of 9,685 PCI patients, carriage of even 1
loss-of-function CYP2C19 allele was significantly associ-
ated with adverse events including ST (100); however, 1
smaller study (n  760) suggested that genotyping may
not be helpful (101). Bonello et al. (102) demonstrated
that tailored clopidogrel dosing can be used to achieve
adequate platelet inhibition in patients carrying the
CYP2C19*2 loss-of-function polymorphism. In contrast,
the CYP2C19*17 allelic variant appears to result in en-
hanced response to clopidogrel and an increased risk of
bleeding (103). In another study, polymorphisms of
ABCB1 also were found to be associated with reduced
platelet inhibition and increased risk of ischemic events
during clopidogrel therapy (104).
DRUG INTERACTIONS. Recently, there has been controversy
about use of proton pump inhibitors (PPI) in patients
requiring clopidogrel. An expert consensus document on
this topic was published in 2010 (105). In brief, routine PPI
are recommended in patients with prior gastrointestinal
bleeding, and multiple risk factors for gastrointestinal bleed-
ing, but not patients at low risk for gastrointestinal bleeding.
Concomitant use of PPI (especially omeprazole) does ap-
pear to reduce the antiplatelet effect of clopidogrel, irrespec-
tive of when the PPI is given (106), but recent studies
suggest that this drug interaction does not significantly
impact clinical outcomes (107). In other studies, the addi-
tion of omega-3 ethyl esters or cilostazol to aspirin and
clopidogrel were shown to potentiate the effect of standard
DAPT (108,109).
P2Y12 inhibitors. Mahoney et al. (110) performed a cost
nalysis of the TRITON–TIMI 38 (Trial to Assess Im-
rovement in Therapeutic Outcomes by Optimizing Plate-
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Infarction 38). At a median follow-up of 14.7 months,
average total costs were $221 lower with prasugrel compared
with clopidogrel, largely due to a lower rate of rehospital-
ization with prasugrel.
Ticagrelor is an oral reversible adenosine diphosphate
inhibitor with more rapid and consistent platelet inhibition
than clopidogrel. Results of 2 planned substudies of the
PLATO (Platelet Inhibition and Patient Outcomes) trial
were published in 2010. In patients with STEMI (n 
8,430) and ACS patients with a planned invasive strategy
(n  13,408), ticagrelor was associated with significant
eductions in death, MI, and ST without an increased risk
f major bleeding (111,112). Similar benefits were observed
n a subgroup with chronic kidney disease (creatinine
learance60 ml/min) (113). In other substudies, ticagrelor
as shown to achieve greater platelet inhibition than clopi-
ogrel, both after a loading dose and during maintenance
herapy (114). Ticagrelor was also shown to be beneficial in
atients with clopidogrel nonresponsiveness (115). In a
enetic substudy, Wallentin et al. (116) reported that
YP2C19 and ABCB1 polymorphisms did not influence
hat efficacy of ticagrelor. Finally, Bellemain-Appaix et al.
117) performed a meta-analysis of 8 randomized trials that
ompared new P2Y12 inhibitors with clopidogrel. All-cause
ortality was significantly decreased for PCI patients,
specially among those with STEMI (odds ratio: 0.78, 95%
onfidence interval: 0.66 to 0.92, p  0.003). Stent throm-
osis was also significantly lower in PCI patients (decreased
0%). These agents, therefore, represent an important step
orward in antiplatelet therapy for PCI patients.
Elinogrel, a reversible, competitive P2Y12 inhibitor that
an be administered both orally and intravenously (half-
ife 12 h), also appeared promising in a phase II clinical
rial (118).
lycoprotein IIb/IIIa inhibitors. Several trials in 2010
xpanded the evidence base regarding the benefits of glyco-
rotein IIb/IIIa inhibitors in primary PCI, and in particular,
he role of small molecule agents. In a 427-patient random-
zed trial, eptifibatide was found to result in similar rates of
omplete ST-segment resolution after PCI compared with
bciximab (119). In a large Swedish registry of 11,479
TEMI patients, similar rates of death/myocardial infarc-
ion at 1 year were observed in patients receiving either
bciximab or eptifibatide (15.7% vs. 15.0%), suggesting the
mall molecule agent is noninferior to abciximab (120).
arly, pre-hospital administration of tirofiban in STEMI
lso appears to be beneficial, with improved 30-day and
-year clinical outcomes (121). A meta-analysis of random-
zed trials with tirofiban in ACS and PCI suggested
irofiban reduces mortality, but an early ischemic hazard was
bserved with tirofiban when compared with abciximab in
tudies with the lower 10 g/kg dose (but not 25 g/kg
ose) (122).
Two studies evaluated intracoronary versus intravenousIV) administration of glycoprotein IIb/IIIa agents. Deibele mt al. (123) randomly assigned ACS patients to intracoro-
ary or IV eptifibatide. Intracoronary eptifibatide resulted in
igher local platelet IIb/IIIa receptor occupancy and im-
roved microvascular perfusion as measured by the cor-
ected TIMI frame count. In another trial, Gu et al. (124)
ompared intracoronary versus IV abciximab in STEMI
atients, and found no difference in the incidence of
omplete ST-segment resolution, but higher rate of myo-
ardial blush grade 2/3 and lower enzymatic infarct size in
he intracoronary group.
ow-molecular-weight heparin. Montalescot et al. (125)
resented results of a randomized trial of IV enoxaparin (0.5
g/kg with or without glycoprotein IIb/IIIa inhibitor)
ersus unfractionated heparin (UFH) in primary PCI. At 30
ays, the primary endpoint (death, complications of MI,
rocedural failure, and non-CABG major bleeding) was
ower in the enoxaparin arm (28.0% vs. 33.7%, p 0.07). A
ower incidence of ischemic endpoints was also observed
ith enoxaparin. Rao et al. (126) reported results of a safety
nd feasibility trial of a novel low-molecular weight heparin
M118) in elective PCI (126). Advantages of this new agent
nclude potent activity against factor Xa and IIa, monitoring
y use of point-of-care assays, and reversibility with
rotamine.
The optimal UFH dosing regimen was studied in 2,026
igh-risk non-STEMI patients initially treated with fonda-
arinux and referred for early coronary angiography (127).
atients were randomly assigned to receive either low-dose
FH (50 U/kg) or standard-dose UFH (85 U/kg) adjusted
y blinded activated clotting time. The primary outcome, a
omposite of major bleeding, minor bleeding, or major
ascular access-site complications up to 48 h, occurred in
.7% in the low-dose group and 5.8% in the standard-dose
roup (p 0.27). At this time, therefore, ACS patients who
re initially treated with fondaparinux should continue to
eceive activated clotting time-guided standard-dose UFH
uring PCI.
tatins. Statin pre-treatment has been shown to reduce
eriprocedural myocardial injury during elective PCI. In a
orean study, 171 STEMI patients were randomly assigned
o high-dose atorvastatin (80 mg) or atorvastatin 10 mg
efore primary PCI (128). At 30 days, the incidence of
ACE was similar between groups; however, myocardial
erfusion was improved in the high-dose arm (assessed by
T-segment resolution, myocardial blush grade, and cor-
ected TIMI frame count). Winchester et al. (129) provided
meta-analysis of 21 trials of pre-procedure statin therapy,
nd demonstrated a reduction in MI in both PCI and
oncardiac surgical procedures, but not CABG.
eripheral Vascular Disease
enal denervation. In one of the most exciting develop-
ents of the year, results of a 106-patient randomized trial
f catheter-based renal sympathetic denervation for treat-
ent of resistant hypertension (systolic blood pressure
2215JACC Vol. 57, No. 22, 2011 Dixon and Grines
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medications) were published (130). At 6 months, the
office-based blood pressure was substantially lower in pa-
tients treated with renal denervation (decrease 32/12 mm
Hg vs. no difference in the control group) (Fig. 3). Eighty-
four percent of renal denervation patients had a reduction in
systolic blood pressure 10 mm Hg versus 35% of controls
(p  0.0001). There were no device-related complications.
Future studies will evaluate the effectiveness of this innova-
tive technique in treating patients with mild hypertension,
congestive heart failure, and other disease states.
Carotid disease. The optimal revascularization strategy for
carotid artery disease remains controversial, but several
studies in 2010 provided important additional data. In the
CREST (Carotid Revascularization Endarterectomy vs.
Stenting Trial), 2,502 symptomatic or asymptomatic pa-
tients were randomly assigned to either carotid artery
stenting (CAS [embolic protection used in 96.1%]) or
carotid artery endarterectomy (CEA) (131). During the
periprocedural period, there was a higher risk of stroke with
stenting (4.1% vs. 2.3%, p  0.01) but lower risk of MI
(1.1% vs. 2.3%, p  0.03). At a median follow-up of 2.5
years, however, there was no difference in the primary
endpoint of stroke, MI, or death between the treatment
groups. In another randomized trial, ICSS (International
Carotid Stenting Study), which studied 1,713 symptomatic
patients, results of an interim safety analysis were published
(132). At 120 days, the incidence of disabling stroke or
Figure 3 Paired Changes in Office-Based Measurements of Sys
Paired changes in office-based measurements of systolic blood pressure (SBP) an
for renal denervation group (light blue bars) and control group (dark blue bars) (1death was 4.0% with stenting versus 3.2% with CEA. Therate of cranial nerve palsy was substantially lower with CAS
(1 event vs. 43 events). Results of the primary endpoint of
the trial (the 3-year rate of fatal or disabling stroke) are
awaited. The same investigators also performed a meta-
analysis of short-term outcomes (120 days) in 3 randomized
trials of symptomatic patients (n  3,433), and reported a
higher risk of death or stroke with CAS versus CEA in
patients ages 70 years or older (12.0% vs. 5.9%), but similar
outcomes in younger patients (133). In another report,
Bangalore et al. (134) performed a propensity-matched
analysis of 3,412 patients in a large registry and observed
similar late outcomes (2 years) between CAS and CEA.
Proximal embolic protection appears to be an alternative
protection strategy among patients undergoing CAS. In a
registry of 1,300 patients, Stabile et al. (135) reported a high
procedural success with the technique and overall 30-day
risk of death or stroke of 1.38%.
The impact of training for CAS was evaluated in the
CASES-PMS (Carotid Artery Stenting With Embolic
Protection Surveillance–Post-Marketing Study). Schreiber
et al. (136) reported that physicians with varied experience
can achieve short- and long-term results similar to those
seen in randomized trials with a formal training program.
Aortic aneurysm. Long-term outcomes from 2 random-
ized trials evaluating endovascular repair of abdominal aortic
aneurysm were published by the EVAR (Endovascular
Aneurysm Repair) study investigators in 2010 (137,138). In
the EVAR-1 trial, 1,252 patients with aortic aneurysm
and Diastolic Blood Pressure
tolic blood pressure (DBP) at 1, 3, and 6 months
NOVA  analysis of variance.tolic
d dias
30). A(5.5 cm diameter) were randomly allocated to endovascu-
2216 Dixon and Grines JACC Vol. 57, No. 22, 2011
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there was no difference in all-cause mortality between
treatment arms. The previously reported early survival
advantage of endovascular repair was lost by 4 years, due to
an increase in aneurysm-related mortality. Additionally,
endovascular repair was associated with higher rates of
graft-related complications and reintervention. In the
EVAR-2 trial, 404 patients deemed physically ineligible for
open repair were randomly allocated to endovascular repair
or no repair (median follow-up was 3.1 years). Endovascular
repair was associated with a lower rate of aneurysm-related
mortality than no repair; however, there was no difference in
overall all-cause mortality, with very few patients surviving
after 8 years.
Peripheral vascular disease. Several studies in 2010 eval-
uated strategies to improve the results of endovascular
intervention in lower extremity arterial disease. In 206
patients with symptomatic superficial femoral artery disease,
implantation of a self-expanding nitinol stent was shown to
improve acute and long-term outcomes compared with
balloon angioplasty with provisional stent implantation
(139). At 12 months, there was a significantly lower rate of
revascularization and higher patency rate (by Duplex ultra-
sonography) in the stent group. In a small randomized trial,
use of a paclitaxel-coated balloon was found to significantly
reduce angiographic late loss compared with balloon angio-
plasty alone (140). In another report, implantation of a PES
was associated with higher 12-month patency than either
angioplasty alone or provisional BMS (141).
DES also appear to be beneficial in patients with infr-
apopliteal disease (142). In a 106-patient randomized trial,
implantation of a SES was shown to result in significantly
higher patency rates at 1 year compared with BMS (143).
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